Product Review: Nivolumab (Opdivo®): clinical profile in advanced renal cell carcinoma
This review discusses the evidence on the use of nivolumab (Opdivo®), a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed death-1 (PD-1) receptor and is indicated:
• In combination with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody ipilimumab (Yervoy®) for the treatment of patients with intermediate- or poor-risk (IPR), previously untreated advanced renal cell carcinoma (RCC)
• In combination with the tyrosine kinase inhibitor (TKI) cabozantinib for the first-line treatment of patients with advanced RCC
• As monotherapy for the treatment of patients with advanced clear-cell RCC after prior antiangiogenic therapy.
Based on these indications, and recent data from international guidelines and large-scale, long-term clinical trials, this review highlights the clinical profile of: nivolumab + ipilimumab as a first-line therapy in IPR patients with advanced RCC; and nivolumab monotherapy in previously treated patients with advanced clear-cell RCC. This resource was created with funding from Bristol-Myers Squibb NZ Ltd.
Expert contributor
Dr Carmel Jacobs
Dr Carmel Jacobs is a Medical Oncologist at Auckland City Hospital and Canopy Cancer Care. Carmel specialises in the treatment of genitourinary and prostate cancers. Carmel graduated from the Otago University School of Medicine in 2001 with Distinction. She completed training in oncology in 2011 with dual specialist training in Internal Medicine in 2012. Between […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
